Will Investors Now Buy Keane Group (FRAC) Stock Following Today's, Citigroup Upgrades?

Gladys Abbott
February 17, 2018

Ocwen Financial Corporation earnings have declined with an annualized rate of -33.7% over the last 5 years.

A number of other research firms have also recently commented on CRL. (NYSE:FRAC) on Thursday, December 21 with "Buy" rating. (NYSE:CRL). Charles River Laboratories International, Inc. has had 20 insider trades in the last 3 months, including 5 open market buys and 15 sells. Robert W. Baird set a $117.00 price target on shares of Charles River Laboratories Intl. and gave the stock a buy rating in a report on Monday, November 13th.

Once the deal is complete, MPI will be organized under Charles River's Discovery and Safety Assessment (DSA) business unit, which accounted for just over half of the CRO's $1.86 billion in total revenues past year. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. $19.78's average target is 41.39% above currents $13.99 stock price. Inc (NYSE:CRL) by 5.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The company now has a consensus rating of "Buy" and a consensus target price of $115.15. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.88 and a quick ratio of 1.62.

Charles River Laboratories International's track record can be a valuable insight into its earnings performance, but it certainly doesn't tell the whole story. (NASDAQ:CRL) to report earnings on Feb, 13 for the fiscal quarter ending Dec 2017.

For the year, the company reported profit of $123.4 million, or $2.54 per share. The firm had revenue of $478.50 million during the quarter, compared to the consensus estimate of $475.02 million.

More news: PM Turnbull Announces Changes To Ministerial Standards Following Barnaby Joyce Saga

The MPI acquisition is expected to close early in the second quarter of this year. CDK Global had 15 analyst reports since August 14, 2015 according to SRatingsIntel. 24,759 shares were sold by JOHST DAVID P, worth $2.72 million on Thursday, October 5. The stock was sold at an average price of $102.40, for a total value of $1,047,244.80. These holdings make up 97.28% of the company's outstanding shares. The disclosure for this sale can be found here. The stock decreased 2.86% or $2.05 during the last trading session, reaching $69.57. Insider ownership increased by a total of 9375 shares, which suggests that CRL's key executives are feeling more optimistic about the outlook for the stock. (NYSE:CRL) have caught the attention of investors. Zions Bancorporation bought a new position in Charles River Laboratories Intl. during the third quarter worth about $212,000. Balyasny Asset Ltd Com invested in 1,972 shares. New York-based Loews has invested 0% in Charles River Laboratories International, Inc. The total dollar value of all 10.09 billion outstanding shares is 314.52 billion. About 7,260 shares traded.

Charles River Laboratories International Inc., a Wilmington company that contracts with drug and medical device makers to test products in mice and rats, said Tuesday that it will pay $800 million to buy a MI firm that does similar work.

The top 5 institutional holders, in ascending order, are as follows: VANGUARD GROUP INC with 4.99 million shares, BLACKROCK INC. with 4.03 million shares, FMR LLC with 2.96 million shares, ARIEL INVESTMENTS, LLC with 1.68 million shares, and AQR CAPITAL MANAGEMENT LLC with 1.51 million shares. "(CRL) Price Target Increased to $120.00 by Analysts at JPMorgan Chase & Co." was first reported by Week Herald and is the sole property of of Week Herald.

Charles River has entered into an agreement to acquire MPI Research of Mattawan, Mich. MPI is a "contract research organization" that helps pharmaceutical and medical device companies that outsource some research and development. It operates through three divisions: Research Models and Services, Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The original version of this story can be accessed at https://stocknewstimes.com/2018/02/15/charles-river-laboratories-intl-inc-crl-stake-raised-by-us-bancorp-de.html. But during the earnings call Tuesday morning, Foster still reaffirmed investors the company's long-term target of low-single-digit revenue growth for RMS, driven by significant growth opportunities from China.

More notable recent Charles River Laboratories International, Inc.

Other reports by LeisureTravelAid

Discuss This Article